Fund Details
BTG International
Overview
Pharmaceutical company specializing in interventional medicine and oncology
Founded
1948
Deals · 12mo
0
Links
Stage focus
Series D
Geographic focus
United Kingdom
Sector focus
Biopharma
Emergency Medicine
Health Care
Manufacturing
...
Investment portfolio
- Xention
Participated · Series D · Nov 2010
Xention discovers and develops ion channel‑modulating drugs. Its lead development focus is on novel therapies for atrial fibrillation, with plans to advance to clinical proof of concept. The company also has drug candidates targeting overactive bladder and autoimmune disease. Xention recently completed an £8m Series D financing. The funding will support progression of its clinical programs. The company is headquartered in Cambridge, UK.